Ethyl 3-chloroimidazo[1,5-a]pyridine-1-carboxylate, 95.0%, 100mg

(2R,4S)-ETHYL 5-([1,1'-BIPHENYL]-4-YL)-4-AMINO-2-METHYLPENTANOATE HCL, 95.0%, 1g

2-Methyloxan-4-amine, 97%, 1g

6-Amino-3H-quinazolin-4-one, 95.0%, 1g

N-(5-acetyl-1,3-thiazol-2-yl)-2,2-dimethylpropanamide, 95.0%, 5g

Ethyl 2,4,6-trifluorobenzoate, 1g

2-oxo-1H,2H,3H-pyrrolo[2,3-b]pyridine-4-carbonitrile, 95.0%, 100mg

Salicylaldehyde, min. 99%, for synthesis, 100 ml, glass packaging

E-plan EPL S60x/0.85 objective. Working distance 0.20 mm

(S)-tert-Butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate, 97%, 5g

(S)-2-Pyrrolidone-5-carboxylic acid t-butyl ester, 95.0%, 100g

3-(1H-pyrrol-1-yl)-1-propanamine, 95.0%, 250mg

Methyl 3-Oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate, 97.0%, 5g